Asia: Intellectual Property

중국 충칭 제1중급인민법원이 ZTE와 삼성전자 간 표준필수특허(SEP) 분쟁에서 7억 3100만 달러 규모의 특허 사용료를 책정한 반면, 영국 런던 고등법원은 같은 날 3억 92

China is undertaking a significant revision of its Trademark Law, introducing changes that will fundamentally impact how brand owners protect and enforce their trademark rights in the Chinese market.

In Al-Hamd Tradenation v. Phonographic Performance Limited, 2025:DHC:3695, the Delhi High Court delivered an important judgment clarifying the scope of compulsory licensing under Section 31 of the Copyright Act, 1957 and held that a copyright owner cannot defeat public access to copyrighted works by imposing arbitrary or unreasonable licensing conditions.

동 보고서는 제14차 5개년 규획 기간 및 2025년 중국 정부가 수행한 권리 침해 및 위조 단속 업무 조치와 관련 성과를 정리한 것으로, 주요내용은 다음과 같다...

The Supreme People's Court recently concluded a dispute over trade secret dispute. In its ruling, the Court established that: If a right holder, through repeated experiments...

技术秘密作为知识产权体系的重要组成部分，是企业核心竞争力的关键载体。最新发布的《最高人民法院知识产权法庭年度报告（2025）》显示，最高人民法院知识产权法庭建庭以来受理技术秘密侵权实体案件343件、审结334件，其中2025年审结51件。研读最高院的裁判思路无疑是办理技术秘密案件的必#

China has launched a nationwide campaign to crack down on online copyright infringement and piracy, with a focus on films and TV dramas, cultural and creative products, books and artificial intelligence-related copyright violations.

A conference on challenges and solutions in emerging areas of online copyright protection was held on Friday in Shenzhen, Guangdong province, calling for further improvements to the copyright legal framework and stronger application of artificial intelligence in the copyright sector

중국 해관총서가 발표한 2025년 지식재산권 보호 현황 보고서는 해관의 집행 활동과 성과를 상세히 다루고 있다. 연간 5만 3,400회의 보호 조치를 통해 8,642만 점의 침&

New Zealand's Parliament has passed the Patents Amendments Bill 2025, addressing a long-standing inconsistency in patent law regarding divisional applications filed under the old Patents Act 1953.

The six-year protection applies to innovative drugs and originator drugs, calculated from the date of drug registration. Improved new drugs receive four years of data protection, and first generic drugs receive three years, according to a guideline issued by the administration. Ordinary generic drugs and biosimilars are not granted data protection.

China's rapid rise in innovation-driven industries is being matched by steady progress in intellectual property protection, as improved legal frameworks and growing international engagement inject new momentum into the country's IP ecosystem, said Etienne Sanz de Acedo, chief executive officer of the International Trademark Association